<?xml version="1.0" encoding="utf-8"?>
<Document>
  <Do_id>19735005</Do_id>
  <Journal>Acta radiologica (Stockholm, Sweden : 1987)</Journal>
  <Doc_title>Imaging of gastrointestinal stromal tumors before and after imatinib mesylate therapy.</Doc_title>
  <Doc_abstract>Gastrointestinal stromal tumors (GISTs) account for the majority of gastrointestinal mesenchymal tumors. Recent advances in treatment using the molecular targeting agent imatinib mesylate have shown startling response rates and variegated imaging findings. We present the various imaging appearances of GIST on computed tomography (CT) and magnetic resonance imaging (MRI), both before and after treatment.</Doc_abstract>
  <Doc_ChemicalList>Antineoplastic Agents;Benzamides;Contrast Media;Piperazines;Pyrimidines;Imatinib Mesylate</Doc_ChemicalList>
  <Doc_meshdescriptors>Antineoplastic Agents;Benzamides;Contrast Media;Disease Progression;Gastrointestinal Stromal Tumors;Humans;Imatinib Mesylate;Magnetic Resonance Imaging;Neoplasm Recurrence, Local;Outcome Assessment (Health Care);Piperazines;Predictive Value of Tests;Pyrimidines;Tomography, X-Ray Computed</Doc_meshdescriptors>
  <Doc_meshqualifiers>therapeutic use;diagnostic imaging;drug therapy;pathology;methods;therapeutic use;therapeutic use</Doc_meshqualifiers>
</Document>
